Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
PLoS Pathog ; 18(7): e1010647, 2022 07.
Artículo en Inglés | MEDLINE | ID: mdl-35776778

RESUMEN

Staphylococcus aureus persistently colonises the anterior nares of a significant proportion of the healthy population, however the local immune response elicited during S. aureus nasal colonisation remains ill-defined. Local activation of IL-17/IL-22 producing T cells are critical for controlling bacterial clearance from the nasal cavity. However, recurrent and long-term colonisation is commonplace indicating efficient clearance does not invariably occur. Here we identify a central role for the regulatory cytokine IL-10 in facilitating bacterial persistence during S. aureus nasal colonisation in a murine model. IL-10 is produced rapidly within the nasal cavity following S. aureus colonisation, primarily by myeloid cells. Colonised IL-10-/- mice demonstrate enhanced IL-17+ and IL-22+ T cell responses and more rapidly clear bacteria from the nasal tissues as compared with wild-type mice. S. aureus also induces the regulatory cytokine IL-27 within the nasal tissue, which acts upstream of IL-10 promoting its production. IL-27 blockade reduces IL-10 production within the nasal cavity and improves bacterial clearance. TLR2 signalling was confirmed to be central to controlling the IL-10 response. Our findings conclude that during nasal colonisation S. aureus creates an immunosuppressive microenvironment through the local induction of IL-27 and IL-10, to dampen protective T cell responses and facilitate its persistence.


Asunto(s)
Interleucina-27 , Infecciones Estafilocócicas , Animales , Citocinas , Terapia de Inmunosupresión , Interleucina-10 , Interleucina-17 , Ratones , Infecciones Estafilocócicas/microbiología , Staphylococcus aureus
2.
JCI Insight ; 9(13)2024 May 28.
Artículo en Inglés | MEDLINE | ID: mdl-38973612

RESUMEN

Staphylococcus aureus is a major human pathogen. An effective anti-S. aureus vaccine remains elusive as the correlates of protection are ill-defined. Targeting specific T cell populations is an important strategy for improving anti-S. aureus vaccine efficacy. Potential bottlenecks that remain are S. aureus-induced immunosuppression and the impact this might have on vaccine-induced immunity. S. aureus induces IL-10, which impedes effector T cell responses, facilitating persistence during both colonization and infection. Thus, it was hypothesized that transient targeting of IL-10 might represent an innovative way to improve vaccine efficacy. In this study, IL-10 expression was elevated in the nares of persistent carriers of S. aureus, and this was associated with reduced systemic S. aureus-specific Th1 responses. This suggests that systemic responses are remodeled because of commensal exposure to S. aureus, which negatively implicates vaccine function. To provide proof of concept that targeting immunosuppressive responses during immunization may be a useful approach to improve vaccine efficacy, we immunized mice with T cell-activating vaccines in combination with IL-10-neutralizing antibodies. Blocking IL-10 during vaccination enhanced effector T cell responses and improved bacterial clearance during subsequent systemic and subcutaneous infection. Taken together, these results reveal a potentially novel strategy for improving anti-S. aureus vaccine efficacy.


Asunto(s)
Interleucina-10 , Infecciones Estafilocócicas , Vacunas Estafilocócicas , Staphylococcus aureus , Interleucina-10/metabolismo , Interleucina-10/inmunología , Animales , Infecciones Estafilocócicas/prevención & control , Infecciones Estafilocócicas/inmunología , Vacunas Estafilocócicas/inmunología , Ratones , Staphylococcus aureus/inmunología , Femenino , Ratones Endogámicos C57BL , Células TH1/inmunología , Inmunización/métodos , Humanos , Anticuerpos Neutralizantes/inmunología , Eficacia de las Vacunas , Vacunación/métodos
3.
Front Immunol ; 11: 767, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32425944

RESUMEN

The lung is under constant pressure to protect the body from invading bacteria. An effective inflammatory immune response must be tightly orchestrated to ensure complete clearance of any invading bacteria, while simultaneously ensuring that inflammation is kept under strict control to preserve lung viability. Chronic bacterial lung infections are seen as a major threat to human life with the treatment of these infections becoming more arduous as the prevalence of antibiotic resistance becomes increasingly commonplace. In order to survive within the lung bacteria target the host immune system to prevent eradication. Many bacteria directly target inflammatory cells and cytokines to impair inflammatory responses. However, bacteria also have the capacity to take advantage of and strongly promote anti-inflammatory immune responses in the host lung to inhibit local pro-inflammatory responses that are critical to bacterial elimination. Host cells such as T regulatory cells and myeloid-derived suppressor cells are often enhanced in number and activity during chronic pulmonary infection. By increasing suppressive cell populations and cytokines, bacteria promote a permissive environment suitable for their prolonged survival. This review will explore the anti-inflammatory aspects of the lung immune system that are targeted by bacteria and how bacterial-induced immunosuppression could be inhibited through the use of host-directed therapies to improve treatment options for chronic lung infections.


Asunto(s)
Infecciones Bacterianas/inmunología , Tolerancia Inmunológica , Pulmón/inmunología , Infecciones del Sistema Respiratorio/inmunología , Animales , Anticuerpos Monoclonales/uso terapéutico , Vacuna BCG/uso terapéutico , Infecciones Bacterianas/tratamiento farmacológico , Células Dendríticas/inmunología , Humanos , Interleucina-10/fisiología , Macrófagos Alveolares/inmunología , Células Supresoras de Origen Mieloide/inmunología , Infecciones del Sistema Respiratorio/tratamiento farmacológico , Factor de Crecimiento Transformador beta/fisiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA